Sources

7 Total Sources

Daraxonrasib Reaches Pancreatic Cancer Patients After 13.2-Month Survival Result

Yahoo! Voices17h ago

New Pancreatic Cancer Drug Daraxonrasib Reaches Patients, Doubling Survival

New York Post 17h ago

New pancreatic cancer drug nearly doubles life expectancy

nejm.org17h ago

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine

The Post and Courier17h ago

New pancreatic cancer drug finally reaches Charleston

linkedin17h ago

RASolute 302 Trial Shows Survival Benefit in Pancreatic Cancer | Revolution Medicines posted on the topic | LinkedIn

Instagram17h ago

RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. In the primary endpoint population of patients with RAS G12 mutations, median OS reached 13.2 months

Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial